Priority Health is First Health Plan to Cover FoundationOne® and FoundationOne® Heme to Enhance Precision Cancer Treatment
Coverage for Foundation Medicine's Comprehensive Cancer Genomic Profiles Now Available to Members of
"FoundationOne and FoundationOne Heme results empower physicians to develop an individualized treatment plan based on the unique genomic profile of each patient's tumor," said
Priority Health's positive coverage decision includes FoundationOne, a fully informative genomic profile that interrogates the entire coding region in 315 genes and select introns in 28 genes commonly altered in solid tumors, and FoundationOne Heme, a fully informative genomic profile that analyzes DNA in 405 genes and RNA in 265 genes that are most commonly altered in hematologic malignancies, sarcomas, and select pediatric cancers. Both services inform the appropriate utilization of targeted therapies in alignment with up-to-date medical evidence.
"This positive coverage decision from a leading commercial insurer serves as further validation of the clinical utility of a treatment plan informed by comprehensive genomic profiling of a patient's unique cancer," said
About
About FoundationOne®
FoundationOne, the company's first clinical product, is a fully informative genomic profile for solid tumors used by oncologists to identify the molecular alterations in a patient's tumor and match those alterations with relevant targeted therapies and clinical trials. Using next-generation sequencing in routine cancer specimens, FoundationOne interrogates all genes somatically altered in human cancers that are validated targets for therapy or unambiguous drivers of oncogenesis based on current knowledge. It reveals all classes of genomic alterations including base substitutions, insertions, deletions, copy number alterations and select rearrangements. FoundationOne fits easily into the clinical workflow of the ordering physician, and test results are provided in an easy-to-interpret report supported by a comprehensive review of published literature. FoundationOne is a laboratory-developed test performed at
About FoundationOne® Heme
FoundationOne Heme is a fully informative genomic profile for hematologic cancers (leukemia, lymphoma and myeloma), sarcomas and pediatric cancers, designed to provide physicians with clinically actionable information to guide treatment options for patients based on the genomic profile of their cancer. It is Foundation Medicine's second clinical product and was developed in collaboration with
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the benefits of FoundationOne and FoundationOne Heme to physicians and patients in the treatment of cancer. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that physicians may encounter delays or denials in obtaining coverage and reimbursement decisions for FoundationOne and FoundationOne Heme, that physicians may not be able to obtain access to relevant targeted therapies and clinical trials matched to molecular alterations identified by FoundationOne and FoundationOne Heme as readily as expected; that
Media Contact:
973-271-6085
dan@purecommunicationsinc.com
or
Investor Contact:
ir@foundationmedicine.com
Source:
News Provided by Acquire Media